Filing Details
- Accession Number:
- 0001104659-20-010939
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-05 06:03:41
- Reporting Period:
- 2020-01-31
- Accepted Time:
- 2020-02-05 06:03:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1477845 | Annovis Bio Inc. | ANVS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1315018 | Maria-Luisa Maccecchini | C/O Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 | President And Ceo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-01-31 | 1,600 | $6.00 | 207,942 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 7,937 | $0.00 | 215,879 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 762,896 | $0.00 | 978,775 | No | 4 | C | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2020-01-31 | 11,111 | $0.00 | 7,937 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2020-01-31 | 1,068,054 | $0.00 | 762,896 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
- Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
Billionaire Hedge Funds
